Novo Nordisk A/S

Novo Nordisk A/S Earnings Recaps

NOVO-B.CO Health Care 1 recap
Next earnings: November 4, 2026 (estimated) · full calendar
Q3 2025 Nov 7, 2025

Novo Nordisk reported robust Q3 2025 results, achieving 15% sales growth and 10% operating profit growth, while narrowing guidance due to anticipated lower growth in GLP-1 diabetes and obesity treatments.

Key takeaways
  • Approved Rybelsus with cardiovascular indications in the U.S. and EU, enhancing portfolio in diabetes care.
  • Obesity care sales surged 41%, significantly boosted by a 168% increase in Wegovy, underscoring strong demand.
  • Initiated a company-wide transformation expected to lead to DKK 8 billion in annual savings by 2026, focusing resources on diabetes and obesity.
  • Operational efficiency improvements are anticipated from the reduction of approximately 9,000 global positions, aiming to enhance shareholder returns.
Full recap

Go deeper on NOVO-B.CO and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.